Ligand Platform Patents
LIGAND.224 family, “PRODRUG COMPOUNDS AND THEIR USES” is pending in US (15/118821), CA, CN, EP, IN, JP with priority to 2/11/2015.
|Patent no.||Title||Expected expiry|
|US 10150788||PRODRUG COMPOUNDS AND USES THEROF||2035|
|US 9994600||PRODRUG COMPOUNDS AND USES THEROF||2035|
Pending in CN, EP, HK, JP.
LIGAND.258 family (acetal prodrugs and some platform technology) is pending in the PCT with priority to 1/9/2019.
Design, Synthesis, and Characterization of a Series of Cytochrome P450 3A-Activated Prodrugs (HepDirect Prodrugs) 2004 JACS articles
Liver-targeted drug delivery using HepDirect prodrugs J Pharmacol Exp Ther 2005; 312:554-560.
HepDirect prodrugs for targeting nucleotide-based antiviral durgs to the liver 2006 Investigational Drugs
Antiviral Efficacy upon Administration of a HepDirect Prodrug August 2011, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Liver-targeting prodrug (LTP) technology offers new generation nucleotide antiviral agents. EASL ILC Paris, poster-345 (2018)
Liver-targeting prodrug (LTP) technology offers opportunity of new generation lipid lowering agents. NLA Scientific Sessions LV, poster-219 (2018)